Skip to main content
    M

    Milestone Scientific (MLSS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX

    $0.29
    -0.01 (-4.56%)

    Market Cap: $27.82M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Milestone Scientific (MLSS) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Milestone Scientific (MLSS) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Milestone Scientific reported EPS of -$0.01, in line with the -$0.01 estimate. It beat the EPS estimate in 0 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    23%(9/39)
    Avg Surprise
    -39.10%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.01
    Range-$0.01 - -$0.01
    4 analysts
    Revenue Consensus
    $2.62M
    Range$2.48M - $2.73M
    4 analysts

    Next Report

    MLSS has an expected report date of Mar 29, 2027.

    MLSS Earnings Call

    The latest MLSS earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MLSS beat 9, missed 17 and matched 14. Revenue for the quarter ended Sep 30, 2026 was $2.22M, down 5.9% from $2.36M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.01-$0.01-$0.01 - -$0.010.00%In lineN/A20 up, 0 downNov 13, 2026$2.22M
    Jun 30, 2026-$0.01-$0.01-$0.01 - -$0.010.00%In lineN/A20 up, 0 downAug 13, 2026$2.84M
    Mar 31, 2026-$0.01-$0.01-$0.02 - -$0.010.00%In lineN/A20 up, 1 downMay 13, 2026$2.16M
    Dec 31, 2025-$0.01-$0.01-$0.02 - -$0.010.00%In lineN/A20 up, 1 downMar 31, 2026$2.06M
    Sep 30, 2025-$0.01-$0.01-$0.01 - -$0.010.00%In lineN/A10 up, 0 downNov 13, 2025$2.36M
    Jun 30, 2025-$0.02-$0.01-$0.01 - -$0.01-100.00%MissN/A10 up, 0 downAug 14, 2025$2.32M
    Mar 31, 2025-$0.02-$0.01-$0.01 - -$0.01-100.00%MissN/A10 up, 0 downApr 15, 2025$2.23M
    Dec 31, 2024-$0.03-$0.01-$0.01 - -$0.01-200.00%MissN/A10 up, 0 downMar 28, 2025$2.01M
    Sep 30, 2024-$0.02-$0.01-$0.01 - -$0.01-100.00%MissN/A10 up, 0 downNov 14, 2024$2.51M
    Jun 30, 2024-$0.02-$0.01-$0.01 - -$0.01-100.00%MissN/A10 up, 0 downAug 14, 2024$1.85M
    Mar 31, 2024-$0.02-$0.02N/A0.00%In lineN/AN/AN/AMay 15, 2024$2.25M
    Dec 31, 2023-$0.03-$0.02N/A-50.00%MissN/AN/A0 up, 0 downMar 29, 2024$2.26M
    Sep 30, 2023-$0.02-$0.02N/A0.00%In lineN/AN/A0 up, 0 downNov 14, 2023$2.06M
    Jun 30, 2023-$0.03-$0.02N/A-50.00%MissN/AN/A0 up, 0 downAug 15, 2023$2.91M
    Mar 31, 2023-$0.02-$0.03-$0.03 - -$0.03+33.33%BeatN/A10 up, 0 downMay 11, 2023$2.60M
    Dec 31, 2022-$0.03-$0.03-$0.03 - -$0.030.00%In lineN/A10 up, 0 downMar 31, 2023$2.24M
    Sep 30, 2022-$0.03-$0.03-$0.03 - -$0.030.00%In lineN/A10 up, 0 downNov 15, 2022$2.22M
    Jun 30, 2022-$0.04-$0.03N/A-33.33%MissN/AN/A0 up, 0 downAug 16, 2022$1.65M
    Mar 31, 2022-$0.03-$0.03-$0.03 - -$0.030.00%In lineN/A10 up, 0 downApr 1, 2022$2.70M
    Dec 31, 2021-$0.02-$0.03-$0.03 - -$0.03+33.33%BeatN/A10 up, 0 downMar 31, 2022$2.85M
    Sep 30, 2021-$0.03-$0.03-$0.03 - -$0.020.00%In lineN/A20 up, 0 downNov 15, 2021$2.11M
    Jun 30, 2021-$0.04-$0.02-$0.02 - -$0.02-100.00%MissN/A2N/AAug 16, 2021$2.43M
    Mar 31, 2021-$0.01-$0.02-$0.03 - -$0.02+50.00%BeatN/A2N/AApr 1, 2021$2.92M
    Dec 31, 2020-$0.01-$0.02-$0.02 - -$0.02+50.00%BeatN/A2N/AMar 31, 2021$2.21M
    Sep 30, 2020-$0.02-$0.04-$0.05 - -$0.04+50.00%BeatN/A2N/ANov 17, 2020$1.25M
    Jun 30, 2020-$0.06-$0.04-$0.04 - -$0.04-50.00%MissN/A1N/AAug 14, 2020$167674
    Mar 31, 2020-$0.03-$0.02-$0.02 - -$0.02-50.00%MissN/A1N/AMay 15, 2020$1.81M
    Dec 31, 2019-$0.05-$0.02N/A-150.00%Miss-600.0%N/AN/AMar 30, 2020$2.30M
    Sep 30, 2019-$0.06-$0.01-$0.01 - -$0.01-500.00%MissN/A1N/ANov 14, 2019$1.90M
    Jun 30, 2019-$0.02-$0.02-$0.02 - -$0.020.00%In lineN/A1N/AAug 14, 2019$2.26M
    Mar 31, 2019-$0.02-$0.04-$0.04 - -$0.04+50.00%BeatN/A1N/AApr 1, 2019$1.92M
    Dec 31, 2018$0.01-$0.04N/A+125.00%BeatN/AN/AN/ADec 31, 2018$3.77M
    Sep 30, 2018-$0.12-$0.04N/A-200.00%MissN/AN/AN/ANov 15, 2018$1.62M
    Jun 30, 2018-$0.04-$0.05-$0.05 - -$0.05+20.00%BeatN/A1N/AAug 14, 2018$2.43M
    Mar 31, 2018-$0.06-$0.02-$0.02 - -$0.02-200.00%MissN/A1N/AApr 3, 2018$1.81M
    Sep 30, 2017-$0.04-$0.04N/A0.00%In lineN/AN/AN/ANov 15, 2017$2.85M
    Jun 30, 2017-$0.05-$0.05N/A0.00%In lineN/AN/AN/AAug 14, 2017$2.52M
    Mar 31, 2017-$0.02-$0.06N/A+66.67%BeatN/AN/AN/AApr 3, 2017$3.69M
    Dec 31, 2016-$0.06-$0.05N/A-20.00%MissN/AN/AN/AMar 31, 2017$1.35M
    Sep 30, 2016-$0.05-$0.02N/A-150.00%MissN/AN/AN/ANov 9, 2016$3.19M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.06, after -$0.09 the year before. It was -$0.27 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.06N/A
    Dec 31, 2024-$0.09N/A
    Dec 31, 2023-$0.10N/A
    Dec 31, 2022-$0.13N/A
    Dec 31, 2021-$0.10N/A
    Dec 31, 2020-$0.12N/A
    Dec 31, 2019-$0.15N/A
    Dec 31, 2018-$0.32N/A
    Dec 31, 2016-$0.20N/A
    Dec 31, 2015-$0.27N/A

    Earnings Calls

    The 5 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,000 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20264,9738
    2025Q4Dec 31, 20252,7687
    2025Q3Sep 30, 20254,0277
    2024Q3Sep 30, 20244,0856
    2024Q2Jun 30, 20244,1705

    2026Q1 Earnings Call

    Opening remarks

    James Carbonara Investor Relations Thank you, operator. Before we begin, please note that today's call will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Please refer to our earnings press release as well as our filings with the SEC, including our 2025 Form 10-K for a discussion of these risks. A replay of this call will be available shortly after its conclusion. With that, I'll turn the call over to our CEO, Eric Hines.

    Eric Hines Chief Executive Officer Thank you, James, and good morning, everybody, and thank you for joining our call today. I especially want to thank everybody who participated in our PIPE in April and your continued support for Milestone. It is greatly appreciated. Our first quarter results reflect continued progress as we execute on the foundation we established in 2025. We remain focused on building a disciplined operating model where spending is aligned with revenue generation and clear return on investment. That focus is reflected in our results. We maintained a relatively stable revenue base in the quarter despite the inability to ship certain booked orders to the Middle East due to the ongoing global conflict in the region. Even with that headwind, we reduced operating expenses by approximately $1.3 million or more than 30% year-over-year, significantly narrowing our losses while we align the company for growth. At the same time, we are beginning to see early signs of traction in the areas that we see as key growth drivers. Starting with our dental business, which remains the backbone of the company. We continue to execute on the national rollout of our ambassador program following its expansion in January, resulting in 173 applications, 73 active ambassadors and 25 new demos and multiple new sales. Engagement levels have been encouraging. And while we expect the financial impact to build over time, we believe this initiative is strengthening our commercial presence and positioning us for improved performance in the back half of the year. Internationally, we continue to pursue additional registrations, which we believe can open meaningful new markets over time. Turning to the medical side. CompuFlo continues to gain traction and is becoming an increasingly important part of our growth strategy. In the first quarter, medical revenue more than doubled year-over-year, reflecting early-stage adoption and growing interest from clinicians. While we are still in the early innings, the progress reinforces our view that the CompuFlo represents a significant long-term opportunity for the company. We also continue to build our infrastructure required to support that growth.

    Frequently Asked Questions About MLSS

    When is Milestone Scientific's next earnings date?

    Milestone Scientific's next earnings report is expected for Mar 29, 2027.

    Did MLSS beat earnings estimates last quarter?

    Milestone Scientific reported EPS of -$0.01 for the quarter ended Sep 30, 2026, in line with the -$0.01 estimate.

    What EPS do analysts expect from MLSS next quarter?

    The consensus EPS estimate for Milestone Scientific for the quarter ending Dec 31, 2026 is -$0.01 from 4 analysts, with estimates from -$0.01 to -$0.01.

    How often does MLSS beat earnings estimates?

    Milestone Scientific beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -50.00%.